Pharmaceuticals Ltd.


Inducterm for Induction

  • Inducterm is a large molecule that cannot cross the placental barrier and therefore does not affect the fetus.
  • It will decrease significantly disastrous side effects that currently occur with prostaglandins (i.e. uterine tetany, fetal distress and very rarely, uterine rupture, fetal or maternal death).
  • It will increase patient comfort.
  • It can be administered as an office procedure to outpatients.
  • It can be given locally with no apparent major side effects.
  • It may decrease the rate of cesarean sections that currently cause unnecessary morbidity and pain.
  • It may decrease overall hospitalization expenses, for both mothers and babies.


Various scientific case reports on the use of the Preventerm source molecule report no adverse side effects to the mother or infant

Initial tests of Preventerm have shown a 90% efficacy rate in preventing preterm labor – overwhelmingly more effective than any of the currently available treatment modalities

Preventerm stands to decrease the overall expense of preterm infant health care and will reduce infant mortality as well as post-natal complications considerably

We intend to generate revenue through joint and/or strategic collaborations with large pharmaceutical and biotechnology companies in order to further develop our products, jointly facilitate regulatory approval, and subsequently to bring our products to the global markets

A unique investment opportunity: Patented and patent-pending breakthrough drugs Direct solution to a pressing market need Vast expertise in the OB/Gyn industry Several discrete multi-billion dollar markets Strategic value to large pharmaceutical companies